Deprecated: Creation of dynamic property WhitelabelOptions::$_title is deprecated in /home/grassnews/public_html/wp-content/themes/zox-news/admin/admin-page.php on line 79
Jumia Reports First Quarter 2019 Results – GrassNews
Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Jumia Reports First Quarter 2019 Results

Published

on

Reading Time: 13 minutes

GMV grew by 58%, leading to a 102% increase in
Marketplace revenue

Jumia continued to deliver cost efficiency improvements

JumiaPay entered into a strategic partnership with Mastercard who
also made a €50 million investment in Jumia

LAGOS, Nigeria–(BUSINESS WIRE)–Jumia Technologies AG (NYSE:JMIA) (“Jumia” or the Company) announced
today its financial results for the quarter ended March 31, 2019.

Advertisement
Stake.com

“Jumia delivered excellent results during the first quarter of 2019:
strong GMV growth of 58% leading to 102% growth in marketplace revenue,
year-on-year improvement of 356 basis points of Operating loss as a
percentage of GMV and further development of JumiaPay, highlighted by
the investment by and partnership with Mastercard,” said Sacha
Poignonnec and Jeremy Hodara, co-CEOs of Jumia. “We believe that Jumia
is increasingly relevant for consumers and sellers in Africa. Looking
ahead, we remain focused on our core operations, driving consumer
adoption and engagement on our marketplace, increasing the penetration
of JumiaPay, while continuing to improve our financial profile and
making a sustainable impact on the continent.”

Business highlights

  • The €50 million investment by Mastercard into Jumia, in a concurrent
    private placement with our Initial Public Offering, marked another
    milestone in the development of JumiaPay and a validation of its
    potential. We are partnering with Mastercard on a number of
    initiatives, including the development and marketing of co-branded
    products (i.e., cards, virtual cards and quick response codes).
  • In the first quarter of 2019, our marketplace continued to gain depth
    and diversity as we focused on attracting quality sellers to our
    platform and providing our consumers with an expanding range of
    products and services. An example of this strategy is the partnership
    we announced this quarter with the technology leader Xiaomi. As part
    of this partnership, we are opening the Mi official store on our
    platform with the ability to offer a number of Xiaomi products on an
    exclusive basis. This demonstrates the attractiveness of Jumia as a
    destination of choice for high profile international brands, giving
    them access to millions of potential consumers in Africa with one
    partnership.

Financial highlights

  • Gross Merchandise Volume (“GMV”) grew this quarter by 58% on a yearly
    basis, on the back of strong marketplace growth, leading to a 102%
    increase this quarter in Marketplace revenue on a yearly basis. Our
    strong GMV growth combined with the attractive value proposition we
    offer both sellers and consumers are a key engine of monetization,
    which we derive from diversified revenue streams such as Commissions,
    Fulfillment, Value Added Services, Marketing and Advertising services.
  • Gross Profit margin as a percentage of GMV increased from 5.6% in the
    first quarter of 2018 to 6.5% this quarter, as a result of the
    increased GMV monetization rate. Our Gross Profit also exceeded
    Fulfillment expense this quarter.
  • We continue to have a strong focus on cost efficiency. Leveraging our
    strong brand awareness and highly localized marketing approach, we
    have been able to gain 205bps of marketing efficiency this quarter,
    bringing the Sales & Advertising expense from 7.2% of GMV in the first
    quarter of 2018 to 5.1% in the first quarter of 2019.
  • Adjusted EBITDA loss as a percentage of GMV improved from negative
    19.8% in the first quarter of 2018 to negative 16.4% in the first
    quarter of 2019.

Selected Operational KPIs
         
2018 2019
First Quarter     Second Quarter     Third Quarter     Fourth Quarter First Quarter
                           
GMV1 (€ million)     152     166     198     311 240
LTM Active Consumers2 (million)     3.0     3.2     3.5     4.0 4.3
           

1 GMV corresponds to the total value of orders including shipping
fees, value added tax, and before deductions of any discounts or
vouchers, irrespective of cancellations or returns.

2
Active Consumers means unique consumers who placed an order on our
marketplace within the 12-month period preceding the relevant date,
irrespective of cancellations or returns

  • GMV increased by 57.6% from €152 million in the first quarter of 2018
    to €240 million in the first quarter of 2019, on the back of strong
    growth of both Active Consumers and spend per Active Consumer.
  • The number of Active Consumers at March 31st, 2019 was 4.3 million, up
    from 3.0 million a year ago. We believe that a major driver of our
    Active Consumers growth is the continued expansion of our product
    offering and the growing relevance of our platform, which drives
    consumer adoption and engagement.

Selected Financial Information

1. Revenue

The following table shows a breakdown of revenue, for the first quarters
of 2018 and 2019.

Advertisement
Stake.com
       
For the three months ended March 31st YoY
(€ million) 2018     2019 Change
                   
Marketplace revenue     7.9     16.0     102.3%
Commissions 2.8     5.5 95.5%
Fulfillment 2.3 5.0 116.1%
Marketing 0.3 0.9 200.7%
Value Added Services 2.5 4.6 85.8%
First Party revenue     19.8     15.6     (21.2%)
Platform revenue     27.7     31.7     14.1%
Non-Platform revenue     0.6     0.2     (68.1%)
Revenue     28.3     31.8     12.3%
 
  • First Party/ Marketplace mix. Our primary
    sources of revenue are commissions and fees generated from third-party
    sales (“Marketplace revenue” or “Revenue related to third-party
    sales”) and revenue from sales of goods we undertake ourselves (“First
    Party revenue” or ““Revenue related to first-party sales”). Shifts in
    the mix between first party and marketplace activities trigger
    substantial variations in our Revenue as we record the full sales
    price net of returns as First Party revenue and only commissions and
    fees in the case of Marketplace revenue. Accordingly, we steer our
    operations not on the basis of our total revenue, but rather on the
    basis of Gross profit, as changes between third-party and first-party
    sales mix are largely eliminated at the Gross profit level. Over time,
    it is our goal to reduce the proportion of first party activity in
    favor of third-party activity at group level. This strategy may
    however vary from quarter to quarter and from country to country.
  • Marketplace revenue increased by 102.3%
    in the first quarter of 2019 compared to the first quarter of 2018, on
    the back of strong revenue growth across all components of Marketplace
    revenue, demonstrating our ability to monetize the platform as we
    continue to grow overall GMV.
    • Commissions, which are charged to our sellers, grew by 95.5%
    • Fulfillment, which are delivery fees charged to consumers, grew by
      116.1%
    • Value Added Services, which include revenue from services charged
      to our sellers such as logistics services, packaging, or content
      creation, grew by 85.8%
    • Marketing and advertising, which include performance marketing
      campaigns, or the placement of banners on our platform, grew by
      200.7%
  • First Party revenue decreased by 21.2% as
    we conducted fewer sales of goods on a first party basis. We undertake
    our first party activity in an opportunistic manner to complement the
    breadth of product assortment on our platform, usually in areas where
    we see unmet consumer demand.

2. Gross Profit
       

 

For the three months ended March 31st YoY
(€ million) 2018     2019 Change
                   
Gross profit     8.6     15.7     82.3%
As % of GMV 5.6%     6.5%
 

Gross profit increased by 82.3% from €8.6 million in the first quarter
of 2018 to €15.7 million in the first quarter of 2019, primarily due to
an increase in Marketplace revenue.

Gross profit margin as a percentage of GMVincreased from 5.6% in the
first quarter of 2018 to 6.5% in the first quarter of 2019 as a result
of increased platform monetization.

3. Fulfillment Expense
       
For the three months ended March 31st YoY
(€ million) 2018     2019 Change
                   
Fulfillment expense     (9.6)     (15.2)     59.4%
As % of GMV 6.3%     6.3%
 

Fulfillment expense includes expenses related to services of third-party
logistics providers, expenses related to our network of warehouses and
pick-up stations, including employee benefit expenses. Fulfillment
expense is influenced by a number of factors including:

Advertisement
Stake.com
  • The origin of the goods, for example the cost of shipping a product
    from a cross-border seller based overseas is higher than shipping from
    a local seller
  • The destination of the package and type of delivery, for example main
    city vs. secondary city vs. rural area, and home delivery vs. pick-up
    station
  • The type of goods, for example the cost of delivery is higher for a
    large home appliance than a fashion accessory

Despite an increase this quarter in the freight and shipping expense
portion of Fulfillment expense, as a result of higher proportion of
cross-border sales, our Gross Profit exceeded Fulfillment expense this
quarter.

4. Sales & Advertising Expense
       
For the three months ended March 31st YoY
(€ million) 2018     2019 Change
                   
Sales & Advertising expense     10.9     12.3     12.5%
As % of GMV 7.2%     5.1%
 

Our Sales and Advertising expense increased by 12.5% to €12.3 million in
the first quarter of 2019 from €10.9 million in the first quarter of
2018, while we were able to increase our GMV by 57.6% over the same
period. As a result, Sales and Advertising expense as a percentage of
GMV, decreased from 7.2% in the first quarter of 2018 to 5.1% in the
first quarter of 2019, demonstrating the relevance of our marketing
strategy as well as the continuous user adoption of our platform.

5. General and Administrative Expense, Technology
and Content Expense
       
For the three months ended March 31st YoY
(€ million) 2018     2019 Change
   
General and Administrative (“G&A”) expense 17.4 27.8 59.9%
Share-Based Compensation (“SBC”) expense     (3.6)     (4.3)     18.2%
G&A expense, excluding SBC     13.7     23.5     71.0%
As % of GMV     9.0%     9.8%      
Technology & Content expense     5.1     5.9     15.3%
As % of GMV     3.3%     2.4%      
G&A, Technology & Content expense, excluding SBC     18.8     29.3     55.9%
As % of GMV 12.3% 12.2%
 

General and Administrative expense contains wages and benefits,
including share-based payment expense of management, as well as seller
management, commercial development, accounting and legal staff,
consulting expense, audit expense, office rent and related utilities,
insurance and other overhead expense.

General and Administrative expense excluding SBC increased by 71.0% from
€13.7 million in the first quarter of 2018 to €23.5 million in the first
quarter of 2019. As a percentage of GMV, General & Administrative
expense excluding SBC, increased from 9.0% in the first quarter of 2018
to 9.8% in the first quarter of 2019, as the improvements due to
operating leverage were more than offset by non-recurring expenses
concomitant with the IPO.

Advertisement
Stake.com

Technology and Content expense increased by 15.3% from €5.1 million in
the first quarter of 2018 to €5.9 million in the first quarter of 2019.
As a percentage of GMV, Technology and content expense, decreased from
3.3% in the first quarter of 2018 to 2.4% in the first quarter of 2019,
as a result of operating leverage.

6. Operating Loss and Adjusted EBITDA
   
For the three months ended March 31st
(€ million) 2018     2019
   
Operating loss (34.3) (45.5)
Depreciation and amortization 0.5 1.7
Share-Based Compensation (“SBC”) expense     3.6     4.3
Adjusted EBITDA     (30.2)     (39.5)
As % of GMV (19.8%) (16.4%)
 

Adjusted EBITDA loss, as a percentage of GMV improved from negative
19.8% in the first quarter of 2018 to negative 16.4% in the first
quarter of 2019 as a result of a higher gross profit margin as a
percentage of GMV, marketing efficiencies and operating leverage
improving Technology & Content expense as a percentage of GMV.

On January 1, 2019, we adopted IFRS 16 accounting guidance amending the
accounting for leases. This led to a reduction of G&A by approximately
€1.1 million in the first quarter of 2019 and an increase in
Depreciation and amortization by approximately €1.3 million, resulting
in a positive impact on Adjusted EBITDA of €1.1 million in the first
quarter of 2019 and a negative impact on Operating loss of €0.2 million.
Prior period amounts were not retrospectively adjusted.

7. Net IPO Proceeds

Advertisement
Stake.com

As of March 31st, 2019, we had €132.2 million of Cash and cash
equivalent on the balance sheet.

After the balance sheet date, we completed our Initial Public Offering.
The net proceeds from our Initial Public Offering, the investment by
Mastercard, the issuance of anti-dilution shares to certain of our
existing shareholders and the exercise by the underwriters of their
option to purchase additional ADRs added $280.2 million to our cash and
cash equivalents in April 2019.

Conference Call and Webcast information

Jumia will host a conference call today, May 13, 2019 at 8:30 a.m. U.S.
Eastern Time to discuss Jumia’s results. Details of the conference call
are as follows:

Participant Dial in (Toll Free): 1-888-317-6016

Advertisement
Stake.com

Participant International Dial in: 1-412-317-6016

Canada Toll Free: 1-855-669-9657

A live webcast of the earnings conference call can be accessed on the
Jumia Investor Relations website: https://investor.jumia.com/

An archived webcast will be available following the call.

(UNAUDITED)

Advertisement
Stake.com

Consolidated statement of comprehensive income
for the quarters ended March 31, 2019 and 2018
     
For the three months ended
March 31       March 31
In millions of EUR       2019       2018
 
 
Revenue 31.8 28.3
Cost of revenue       16.2       19.8
Gross profit 15.7 8.6
 
Fulfillment expense 15.2 9.6
Sales and advertising expense 12.3 10.9
Technology and content expense 5.9 5.1
General and administrative expense 27.8 17.4
Other operating income 0.1 0.1
Other operating expense       0.0       0.0
Operating loss (45.5) (34.3)
 
Finance income 0.6 0.6
Finance costs       0.8       0.3
Loss before Income tax (45.7) (34.0)
 
Income tax expense       0.1       0.1

Loss for the period

      (45.8)       (34.1)
 
Attributable to:
Equity holders of the Company (45.7) (33.6)
Non-controlling interests       (0.1)       (0.5)

Loss for the period

      (45.8)       (34.1)
 
Other comprehensive income/loss to be classified to profit or
loss in subsequent periods
Exchange differences on translation of foreign operations – net of
tax
(11.9) 6.6
Other comprehensive income / (loss) on net investment in foreign
operations – net of tax
      12.2       (6.6)
Other comprehensive loss       0.4       (0.1)

Total comprehensive loss for the period

      (45.4)       (34.2)
 
Attributable to:
Equity holders of the Company (45.4) (33.7)
Non-controlling interests       (0.1)       (0.4)

Total comprehensive loss for the period

Advertisement
Stake.com
      (45.4)       (34.2)
 

(UNAUDITED)

Consolidated Statement of financial position as
of March 31, 2019 and 2018
           
As of
March 31 December 31
In millions of EUR       2019       2018
 
 
Assets
 
Non-current assets
Property and equipment 15.5 5.0
Intangible assets 0.1 0.2
Deferred tax assets 0.2 0.2
Other non-current assets       1.4       1.3
Total Non-current assets       17.2       6.6
 
Current assets
Inventories 11.0 9.4
Trade and other receivables 13.3 13.0
Other taxes receivable 5.5 4.9
Prepaid expense and other current assets 12.6 7.4
Cash and cash equivalents       132.2       100.6
Total Current assets       174.7       135.4
Total Assets       191.9       142.0
 
Equity and Liabilities
 
Equity
Share capital 0.1 0.0
Share premium 0.8 0.8
Other reserves 0.1 0.1
Accumulated losses       (0.9)       (0.9)
Equity attributable to the equity holders of the Company 81.1 50.0
Non-controlling interests       (0.2)       (0.1)
Total Equity       80.9       49.8
 
Liabilities
Non-current liabilities 0.0 0.0
Non-current borrowings       6.0       0.0
Total Non-current liabilities       6.0       0.0
 
Current liabilities
Borrowings 3.4 0.0
Trade and other payables 58.6 47.7
Income tax payables 0.1 0.1
Other taxes payable 7.6 7.4
Provisions for liabilities and other charges 31.3 30.4
Deferred income       3.9       6.5
Total Current liabilities       104.9       92.2
Total Liabilities       110.9       92.2
Total Equity and Liablities       191.9       142.0
 

(UNAUDITED)

Consolidated statement of cash flows for the
quarters ended March 31, 2019 and 2018
     
For the three months ended
March 31       March 31
In millions of EUR       2019       2018
 
Loss before Income tax (45.7) (34.0)
 
Depreciation and amortization 1.7 0.5
Impairment losses on loans, receivables and other assets 0.5 0.3
Impairment losses on obsolete inventories 0.2 (0.0)
Share-based payment expense 4.3 3.6
Loss/(Gain) on disposal of property, equipments and intangible assets 0.0 0.0
(Gain) /Loss on disposal of financial assets 0.0 0.0
Net accrued interest and similar (income)/expense 0.2 (0.0)
Net unrealized foreign exchange (gain)/loss (0.1) (0.4)
(Increase)/Decrease in trade and other receivables, prepayments and
VAT receivables
(7.3) 0.6
(Increase)/Decrease in inventories (1.7) 0.8
Increase/(Decrease) in trade and other payables, prepayments and VAT
payables
8.0 (4.7)
Change in provision for other liabilities and charges 0.6 (0.0)
Income taxes paid       (0.1)       0.1
Net cash flows used in operating activities       (39.3)       (33.1)
 
Cash flows from investing activities
Purchase of property and equipment (0.7) (0.5)
Proceeds from sale of property and equipment 0.0 0.0
Purchase of intangible assets 0.0 (0.0)
Consolidated securities investment (0.0) 0.0
Purchase of financial assets (0.0) 0.0
Movement in other non-current assets       0.1       (0.3)
Net cash flows used in investing activities       (0.7)       (0.8)
 
Cash flows from financing activities
Proceeds from borrowings 0.0 0.0
Financial interest paid (0.3) 0.0
Payment of lease liabilities (0.8) 0.0
Capital contributions 75.0 24.0
Expenses reclassed to Equity       (2.7)       0.0
Net cash flows from financing activities       71.2       24.0
Net increase in cash and cash equivalents       31.2       (9.9)
Effect of exchange rate changes on cash and cash equivalents       0.4       (0.4)

Cash and cash equivalents at the beginning of the period

Advertisement
Stake.com
      100.6       29.7

Cash and cash equivalents at the end of the period

      132.2       19.4
 

Non-IFRS and Other Financial and Operating
Metrics

This release includes certain financial measures and metrics not based
on IFRS, including Adjusted EBITDA, as well as operating metrics,
including GMV and Active Consumers. We define GMV, Active Consumers and
Adjusted EBITDA as follows:

GMV corresponds to the total value of
orders including shipping fees, value added tax, and before deductions
of any discounts or vouchers, irrespective of cancellations or returns.

Active Consumers means unique consumers who
placed an order on our marketplace within the 12-month period preceding
the relevant date, irrespective of cancellations or returns.

Advertisement
Stake.com

Adjusted EBITDA corresponds to loss for the
year, adjusted for income tax expense, finance income, finance costs,
depreciation and amortization and share-based payment expense.

Adjusted EBITDA is a supplemental non-IFRS measure of our operating
performance that is not required by, or presented in accordance with,
IFRS. Adjusted EBITDA is not a measurement of our financial performance
under IFRS and should not be considered as an alternative to loss for
the year, loss before income tax or any other performance measure
derived in accordance with IFRS. We caution investors that amounts
presented in accordance with our definition of Adjusted EBITDA may not
be comparable to similar measures disclosed by other companies, because
not all companies and analysts calculate Adjusted EBITDA in the same
manner. We present Adjusted EBITDA because we consider it to be an
important supplemental measure of our operating performance. Management
believes that investors’ understanding of our performance is enhanced by
including non-IFRS financial measures as a reasonable basis for
comparing our ongoing results of operations. By providing this non-IFRS
financial measure, together with a reconciliation to the nearest IFRS
financial measure, we believe we are enhancing investors’ understanding
of our business and our results of operations, as well as assisting
investors in evaluating how well we are executing our strategic
initiatives.

Management uses Adjusted EBITDA:

  • as a measurement of operating performance because it assists us in
    comparing our operating performance on a consistent basis, as it
    removes the impact of items not directly resulting from our core
    operations;
  • for planning purposes, including the preparation of our internal
    annual operating budget and financial projections;
  • to evaluate the performance and effectiveness of our strategic
    initiatives; and
  • to evaluate our capacity to expand our business.

Items excluded from this non-IFRS measure are significant components in
understanding and assessing financial performance. Adjusted EBITDA has
limitations as an analytical tool and should not be considered in
isolation, or as an alternative to, or a substitute for analysis of our
results reported in accordance with IFRS, including loss for the year.
Some of the limitations are:

  • Adjusted EBITDA does not reflect our share-based payments, income tax
    expense or the amounts necessary to pay our taxes;
  • although depreciation and amortization are eliminated in the
    calculation of Adjusted EBITDA, the assets being depreciated and
    amortized will often have to be replaced in the future and such
    measures do not reflect any costs for such replacements; and
  • other companies may calculate Adjusted EBITDA differently than we do,
    limiting its usefulness as a comparative measure.

Due to these limitations, Adjusted EBITDA should not be considered as a
measure of discretionary cash available to us to invest in the growth of
our business. We compensate for these and other limitations by providing
a reconciliation of Adjusted EBITDA to the most directly comparable IFRS
financial measure, loss for the year.

The following tables provide a reconciliation of loss for the year to
Adjusted EBITDA for the periods indicated:
   
For the three months ended March 31st
(€ million) 2018     2019
             
Loss for the period     (34.1)     (45.8)
Income tax expense 0.1     0.1
Finance costs 0.3 0.8
Finance income (0.6) (0.6)
Depreciation and amortization 0.5 1.7
Share-based payment exercise     3.6     4.3
Adjusted EBITDA     (30.2)     (39.5)
 

Advertisement
Stake.com

Contacts

Safae Damir
Head of Investor Relations
investor-relations@jumia.com

Abdesslam
Benzitouni
Head of PR and Communications
press@jumia.com


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center

Published

on

innocan-pharma-submits-investigational-new-animal-drug-application-to-fda’s-veterinary-center

HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.

 

 

The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.  

Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.

Advertisement
Stake.com

“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”

Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”

About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com 

Advertisement
Stake.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Advertisement
Stake.com

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html

Continue Reading

Cannabis

Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location

Published

on

  • Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
  • As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
  • Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity

CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.

The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.

“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”

Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.

About Verano

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf and MÜV dispensary banners, including Cabbage Club, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano, (the) Essence, MÜV, Savvy, BITS, Encore, and Avexia. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.

Advertisement
Stake.com

Contacts:

Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com

Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Advertisement
Stake.com

###


1 Pennsylvania Department of Transportation
2 United States Census Bureau

Continue Reading

Cannabis

Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids

Published

on

Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.

Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.

Global Minor Cannabinoids Market: Key Datapoints
 

Market Value in 2023

Advertisement
Stake.com
 

US$ 17.8 Bn

 

Market Value Forecast by 2034

 
Advertisement
Stake.com

US$ 42.3 Bn

 

Growth Rate

 

 
Advertisement
Stake.com

8.2%

 

Historical Data

 

 
Advertisement
Stake.com

2016 – 2022

 

Base Year

 

 
Advertisement
Stake.com

2023

 

Forecast Data

 

 
Advertisement
Stake.com

2024 – 2034

Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.

Get Sample Copy of the Report

The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.

The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.

Advertisement
Stake.com

The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.

Visit our Homepage

Global Minor Cannabinoids Market: Key Takeaways of the Report

  • Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
  • Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
  • In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.

Key Development:

  • In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
  • In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.

Browse Related Category Reports

Global Minor Cannabinoids Market:

  • Aurora Europe GmbH
  • BulKanna
  • CBD. INC.
  • Fresh Bros Hemp Company
  • GCM Holdings, LLC (Global Cannabinoids)
  • GenCanna.
  • High Purity Natural Products.
  • Laurelcrest
  • Mile High Labs
  • PBG Global
  • Rhizo Sciences
  • ZERO POINT EXTRACTION, LLC
  • Other Industry Participants

Global Minor Cannabinoids Market

By Product Type

Advertisement
Stake.com
  • Cannabigerol (CBG)
  • Cannabichromene (CBC)
  • Cannabinol (CBN)
  • Cannabidivarin (CBDV)
  • Tetrahydrocannabutol (THCB)
  • Tetrahydrocannabivarin (THCV)
  • Tetrahydrocannabiphorol (THCP)
  • Others

By Application

  • Pharmaceutical
    • Pain Management
    • Mental Health
    • Sleep Disorders
    • Anti-inflammatory
    • Others
  • Nutraceuticals
  • Cosmetics and Personal Care
  • Food and Beverages
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)  

Consult with Our Expert:

Jay Reynolds

The Niche Research

Japan (Toll-Free): +81 663-386-8111

South Korea (Toll-Free): +82-808- 703-126

Saudi Arabia (Toll-Free): +966 800-850-1643

Advertisement
Stake.com

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

Email: askanexpert@thenicheresearch.com

Website: www.thenicheresearch.com

Advertisement
Stake.com
Continue Reading
Advertisement
Stake.com

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: sales@hipther.agency

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania